Accessibility Menu
 
Tarsus Pharmaceuticals logo

Tarsus Pharmaceuticals

(NASDAQ) TARS

Current Price$62.41
Market Cap$2.69B
Since IPO (2020)+204%
5 Year+112%
1 Year+44%
1 Month-13%

Tarsus Pharmaceuticals Financials at a Glance

Market Cap

$2.69B

Revenue (TTM)

$535.08M

Net Income (TTM)

$48.27M

EPS (TTM)

$-1.13

P/E Ratio

-55.13

Dividend

$0.00

Beta (Volatility)

0.88 (Low)

Price

$62.41

Volume

14,938

Open

$64.90

Previous Close

$62.41

Daily Range

$61.92 - $65.51

52-Week Range

$38.51 - $85.25

TARS: Motley Fool Moneyball Superscore

78

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tarsus Pharmaceuticals

Industry

Pharmaceuticals

Employees

370

CEO

Bobak Azamian, MD, PhD

Headquarters

Irvine, CA 92618, US

TARS Financials

Key Financial Metrics (TTM)

Gross Margin

90%

Operating Margin

-9%

Net Income Margin

-9%

Return on Equity

-14%

Return on Capital

-12%

Return on Assets

-8%

Earnings Yield

-1.81%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.69B

Shares Outstanding

43.02M

Volume

14.94K

Avg. Volume

628.87K

Financials (TTM)

Gross Profit

$420.68M

Operating Income

$70.97M

EBITDA

$53.61M

Operating Cash Flow

$12.45M

Capital Expenditure

$9.86M

Free Cash Flow

$22.31M

Cash & ST Invst.

$417.27M

Total Debt

$93.64M

Tarsus Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$162.05M

+106.9%

Gross Profit

$152.66M

+108.8%

Gross Margin

94.20%

N/A

Market Cap

$2.69B

N/A

Market Cap/Employee

$8.32M

N/A

Employees

323

N/A

Net Income

$6.97M

+72.3%

EBITDA

$5.68M

+74.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$300.06M

-10.6%

Accounts Receivable

$117.21M

+82.7%

Inventory

$4.57M

+69.0%

Long Term Debt

$88.68M

+23.2%

Short Term Debt

$0.00

-100.0%

Return on Assets

-8.31%

N/A

Return on Invested Capital

-11.61%

N/A

Free Cash Flow

$30.47M

-43.4%

Operating Cash Flow

$24.65M

-19.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ARQTArcutis Biotherapeutics, Inc.
$21.32-1.16%
IRONDisc Medicine, Inc.
$66.86-4.07%
ZLABZai Lab Limited
$20.59+1.28%
ADPTAdaptive Biotechnologies Corporation
$12.83-2.66%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$10.62-0.05%
NOKNokia
$13.95-0.04%
FFord Motor Company
$13.40-0.07%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$15.06-0.10%

Questions About TARS

What is the current price of Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals is trading at $62.41 per share.

What is the 52-week range for Tarsus Pharmaceuticals?

Over the past 52 weeks, Tarsus Pharmaceuticals has traded between $38.51 and $85.25.

How much debt does Tarsus Pharmaceuticals have?

As of the most recent reporting period, Tarsus Pharmaceuticals reported total debt of $88.68M.

How much cash does Tarsus Pharmaceuticals have on hand?

Tarsus Pharmaceuticals reported $102.19M in cash and cash equivalents in its most recent financial results.

What is Tarsus Pharmaceuticals’s dividend yield?

Tarsus Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.